Wockhardt Limited
1,855.50
INR
-21.70
(-1.16%)
ISIN
INE049B01025
Return %
Stock
S&P 500
1Y
35.17
14.20
3Y
659.98
81.12
5Y
349.85
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Murtaza Habil Khorakiwala
- Full Time Employees
- 4,084
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Wockhardt Towers Mumbai MH India 400051
- IPO Date
- Feb 25, 1994
- Website
- wockhardt.com
- Similar Companies
- Business
- Wockhardt Limited is a research-based global pharmaceutical and biotechnology company headquartered in Aurangabad, Maharashtra, India, founded in 1960. The company manufactures, markets, and distributes a broad portfolio of products including branded and generic pharmaceuticals, biopharmaceuticals, sterile injectables, and diabetic care products. Its product offerings encompass therapeutic categories such as anti-infectives, oncology, cardiology, diabetes management, and nutritional products. Wockhardt serves markets in over 75 countries, with significant operations in India, the United States, Europe, and emerging markets. The company operates through multiple business segments: pharmaceutical formulations, biotechnology products including biosimilars and complex generics, specialty injectables, and advanced diabetic care solutions consisting of both medications and monitoring devices. Wockhardt leverages cutting-edge research and development capabilities, investing approximately 8-10% of revenues into innovation to advance new product launches, especially in oncology and biologics. Its manufacturing network is designed to meet stringent global regulatory standards. Recent major changes include the acceptance of its New Drug Application (NDA) for Zaynich, India’s first novel chemical entity, by the US Food and Drug Administration (USFDA), with commercial preparations underway particularly targeting the US market alongside planned launches in India, Europe, and emerging markets by mid-2026. The company has also pursued strategic expansions and partnerships in advanced product portfolios and biosimilars to enhance its global footprint. Financially, Wockhardt reported consolidated revenues of approximately ₹2,329 crore in FY 2023 with a net profit of ₹180 crore, demonstrating operational resilience and growth. Wockhardt remains controlled by the founding Khorakiwala family and is led by key executives including Habil Khorakiwala as Chairman. It continues to focus on innovation-driven growth in the global pharmaceutical and biotechnology sectors, emphasizing affordable, high-quality medicines, and advanced healthcare solutions for chronic diseases and complex conditions. Overall, Wockhardt Limited represents a comprehensive pharmaceutical and biotechnology enterprise with a diversified global product offering, ongoing strategic initiatives in novel drug and biosimilar development, and a robust R&D-led approach to expanding its market presence worldwide.